Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type 1a (CMT 1a), Neuromuscular Disorders, vol.1, issue.2, pp.93-100, 1991. ,
DOI : 10.1016/0960-8966(91)90055-W
Gene dosage is a mechanism for Charcot-Marie-Tooth disease type 1A, Nature Genetics, vol.46, issue.1, pp.29-33, 1992. ,
DOI : 10.1016/0960-8966(91)90055-W
Clinical and electrophysiological aspects of Charcot-Marie-Tooth disease, NeuroMolecular Medicine, vol.8, issue.1-2, pp.3-22, 2006. ,
DOI : 10.1385/NMM:8:1-2:3
Charcot-Marie-Tooth Neuropathy Type 1, GeneReviews, 2014. ,
Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease, Nature Medicine, vol.10, issue.4, pp.396-401, 2004. ,
DOI : 10.1038/nm1023
Ascorbic acid inhibits PMP22 expression by reducing cAMP levels, Neuromuscular Disorders, vol.17, issue.3, pp.248-53, 2007. ,
DOI : 10.1016/j.nmd.2006.12.008
Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial, BMC Medicine, vol.16, issue.1, p.70, 2009. ,
DOI : 10.1016/j.nmd.2006.03.008
Ascorbic acid for Charcot???Marie???Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial, The Lancet Neurology, vol.8, issue.6, pp.537-581, 2009. ,
DOI : 10.1016/S1474-4422(09)70108-5
Poor tolerability of high dose ascorbic acid in a population of genetically confirmed adult Charcot-Marie-Tooth 1A patients, Acta Neurologica Scandinavica, vol.70, issue.2, pp.134-142, 2009. ,
DOI : 10.1111/j.1600-0404.2008.01134.x
Effect of ascorbic acid in patients with Charcot???Marie???Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial, The Lancet Neurology, vol.8, issue.12, pp.1103-1113, 2009. ,
DOI : 10.1016/S1474-4422(09)70260-1
Ascorbic acid in Charcot???Marie???Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial, The Lancet Neurology, vol.10, issue.4, pp.320-328, 2011. ,
DOI : 10.1016/S1474-4422(11)70025-4
High-Dosage Ascorbic Acid Treatment in Charcot-Marie-Tooth Disease Type 1A, JAMA Neurology, vol.70, issue.8, pp.981-988, 2013. ,
DOI : 10.1001/jamaneurol.2013.3178
Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy, Orphanet Journal of Rare Diseases, vol.32, issue.1, p.201, 2014. ,
DOI : 10.1186/s13023-014-0201-x
An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A, Orphanet Journal of Rare Diseases, vol.120, issue.3, p.199, 2014. ,
DOI : 10.1186/s13023-014-0199-0
168th ENMC International Workshop: Outcome measures and clinical trials in Charcot???Marie???Tooth disease (CMT), Neuromuscular Disorders, vol.20, issue.12, pp.839-885, 2010. ,
DOI : 10.1016/j.nmd.2010.08.001
Reliability and validity of the CMT neuropathy score as a measure of disability, Neurology, vol.64, issue.7, pp.1209-1223, 2005. ,
DOI : 10.1212/01.WNL.0000156517.00615.A3
A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale, Journal of Neurology, Neurosurgery & Psychiatry, vol.77, issue.8, pp.973-979, 2006. ,
DOI : 10.1136/jnnp.2005.081547
Neuropathy progression in Charcot-Marie-Tooth disease type 1A, Neurology, vol.70, issue.5, pp.378-83, 2008. ,
DOI : 10.1212/01.wnl.0000297553.36441.ce
Factors That Impact Symptomatic Diabetic Peripheral Neuropathy in Placebo-Administered Patients From Two 1-Year Clinical Trials, Diabetes Care, vol.30, issue.10, pp.2626-2658, 2007. ,
DOI : 10.2337/dc07-0608
Placebo interventions for all clinical conditions, Cochrane Database Syst Rev, issue.1, p.3974, 2010. ,
Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease, Journal of the Peripheral Nervous System, vol.9, issue.3, pp.191-199, 2011. ,
DOI : 10.1111/j.1529-8027.2011.00350.x
Psychometrics evaluation of Charcot-Marie-Tooth Neuropathy Score (CMTNSv2) second version, using Rasch analysis, Journal of the Peripheral Nervous System, vol.6, issue.3, pp.192-198, 2014. ,
DOI : 10.1111/jns.12084
Selected items from the Charcot-Marie-Tooth (CMT) Neuropathy Score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients, Neuromuscular Disorders, vol.24, issue.11, pp.1003-1020, 2014. ,
DOI : 10.1016/j.nmd.2014.06.431